A lung cancer therapy can more than double life expectancy in some patients, a “milestone” trial has shown.
Nivolumab stops cancerous cells hiding from the body’s own defences, leaving the cancer vulnerable to attack.
The results from 582 people were presented at the American Society of Clinical Oncology.
James Gallagher reports.
Lung cancer therapy is ‘milestone’